Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
Recent Articles
RELATED ARTICLES
-
PegBio aims to bulk up its finances to deliver weight-loss drugs
- Innogen Pharma jostles for a slice of the weight-loss market
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
